Cargando…

The effects of chronic glucorticoid stimulation on erythropoiesis in Cushing syndrome

Detalles Bibliográficos
Autores principales:	Strouboulis, John, El Hoss, Sara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071124/ https://www.ncbi.nlm.nih.gov/pubmed/35861018 http://dx.doi.org/10.3324/haematol.2022.281355

Ejemplares similares

Hypersensitivity to glucorticoids in children
por: Vesel, Tina, et al.
Publicado: (2014)

A novel index to evaluate ineffective erythropoiesis in hematological diseases offers insights into sickle cell disease
por: Brewin, John, et al.
Publicado: (2021)

The Pleiotropic Effects of GATA1 and KLF1 in Physiological Erythropoiesis and in Dyserythropoietic Disorders
por: Barbarani, Gloria, et al.
Publicado: (2019)

Erythropoiesis-Stimulating Agent Hyporesponsiveness and Adverse Outcomes: Guilty as Charged?
por: Wish, Jay B.
Publicado: (2020)

Inflammation and Erythropoiesis-Stimulating Agent Hyporesponsiveness: A Critical Connection
por: Shah, Hitesh H., et al.
Publicado: (2020)

Phylogeny and Ontogeny of Erythropoiesis
por: Nunomura, Wataru, et al.
Publicado: (2015)

Subclinical Cushing's Syndrome and Metabolic Disorder
por: Bae, Ji Cheol
Publicado: (2014)

Chronic Restraint Stress Upregulates Erythropoiesis through Glucocorticoid Stimulation
por: Voorhees, Jeffrey L., et al.
Publicado: (2013)

Crosstalk between Erythropoiesis and Iron Metabolism
por: Rivella, Stefano, et al.
Publicado: (2010)

GATA-1 genome-wide occupancy associates with distinct epigenetic profiles in mouse fetal liver erythropoiesis
por: Papadopoulos, Giorgio L., et al.
Publicado: (2013)

Pharmacovigilance in practice: erythropoiesis-stimulating agents
por: Hedenus, Michael, et al.
Publicado: (2014)

The relationship between systemic iron homeostasis and erythropoiesis
por: Rishi, Gautam, et al.
Publicado: (2017)

Protective roles of erythropoiesis-stimulating proteins in chronic heart failure with anemia
por: ZHOU, SHUQIN, et al.
Publicado: (2014)

Role of bilateral adrenalectomy in adrenocorticotropic hormone-dependent Cushing's syndrome
por: Jyotsna, V. P.
Publicado: (2015)

Prediction of Response to Erythropoiesis Stimulating Agents in Low-Risk Myelodysplastic Syndromes
por: Hattakitpanitchakul, Saroj, et al.
Publicado: (2021)

The Death of Dr. Cushing
Publicado: (1900)

No TREATment with Darbepoetin Dosed to Hemoglobin 13 Grams per Deciliter in Type 2 Diabetes with Pre-Dialysis Chronic Kidney Disease - Safety Warnings for Erythropoiesis-Stimulating Agents
por: Curtiss, Frederic R.
Publicado: (2009)

Fetal hemoglobin rescues ineffective erythropoiesis in sickle cell disease
por: El Hoss, Sara, et al.
Publicado: (2020)

Erythropoiesis-stimulating Agents and Anemia in Patients with Non-dialytic Chronic Kidney Disease
por: Kim, Sun Moon, et al.
Publicado: (2016)

The Use of Darbepoetin to Stimulate Erythropoiesis in the Treatment of Anemia of Chronic Kidney Disease in Dogs
por: Fiocchi, E.H., et al.
Publicado: (2017)

Erythropoiesis stimulating agents: approaches to modulate activity
por: Sinclair, Angus M
Publicado: (2013)

Altitude Pre-Acclimatization with an Erythropoiesis-Stimulating Agent
por: Heldeweg, Micah L. A., et al.
Publicado: (2023)

Quantitative assessment of minimal effective concentration of erythropoiesis-stimulating agents
por: Yan, X, et al.
Publicado: (2013)

Different effects of granulocyte colony-stimulating factor and erythropoietin on erythropoiesis
por: Chen, Tzu-Lin, et al.
Publicado: (2018)

Erythropoiesis-stimulating agents and quality of life: personal journeys of a cancer survivor, oncologist, and two cancer health services researchers
por: Bennett, C L, et al.
Publicado: (2014)

Trench coats, Cushing, and Gillies
por: Hwang, Kun
Publicado: (2018)

Erythropoiesis-stimulating agents and cardiovascular events in patients with myelodysplastic syndrome and multiple myeloma
por: Horváth-Puhó, Erzsébet, et al.
Publicado: (2018)

Use of erythropoiesis-stimulating agents in children with chronic kidney disease: a systematic review
por: Bruce, Gordon, et al.
Publicado: (2022)

Responsiveness to an erythropoiesis-stimulating agent is correlated with body composition in patients undergoing chronic hemodialysis
por: Lee, Hyang Yun, et al.
Publicado: (2022)

Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer
por: Smith, R E, et al.
Publicado: (2001)

Factors associated with erythropoiesis-stimulating agent hyporesponsiveness anemia in chronic kidney disease patients
por: Amnuay, Kamalas, et al.
Publicado: (2019)

Cushing’s Syndrome Effects on the Thyroid
por: Paragliola, Rosa Maria, et al.
Publicado: (2021)

USP8 mutation in Cushing's disease
por: Huang, Chuanxin, et al.
Publicado: (2015)

Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer
por: Aapro, M, et al.
Publicado: (2012)

Effect of Erythropoiesis-Stimulating Agents on Blood Pressure in Pre-Dialysis Patients
por: Suttorp, Marit M., et al.
Publicado: (2013)

Development and characterization of novel erythropoiesis stimulating protein (NESP)
por: Egrie, J C, et al.
Publicado: (2001)

Use of erythropoiesis-stimulating agents in obese hemodialysis patients
por: Park, Sun-Hee
Publicado: (2018)

Treatment of renal anemia: Erythropoiesis stimulating agents and beyond
por: Biggar, Patrick, et al.
Publicado: (2017)

Tips for erythropoiesis-stimulating agent treatment of renal anemia
por: Tomosugi, Naohisa, et al.
Publicado: (2019)

Erythropoiesis-Stimulating Agent Treatment in Patients With COVID-19
por: Fishbane, Steven, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pup92be1hmekp12aibrbomssmg